Page 3 - பச்சை குறுக்கு நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பச்சை குறுக்கு நிறுவனம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பச்சை குறுக்கு நிறுவனம் Today - Breaking & Trending Today

GC Pharma : Lights Up to Celebrate 'World Hemophilia Day'


GC Pharma : Lights Up to Celebrate ‘World Hemophilia Day
04/17/2021 | 10:11pm EDT
Send by mail :
Message :
The Company features this year’s slogan image on media façade
GC Pharma (formerly known as Green Cross Corporation), a South Korean biopharmaceutical company, participates in a campaign to celebrate World Hemophilia Day.
As part of GC Pharma’s continued support of the hemophilia community, the company features this year s slogan image on a giant exterior media façade of its main campus in Yongin, South Korea.
Started in 1989 by the World Federation of Hemophilia (WFH), in honor of their founder Frank Schnabel’s birthday, World Hemophilia Day is celebrated each year on April 17 ....

South Korea , South Korean , Frank Schnabel , World Federation Of Hemophilia , Green Cross Corporation , World Hemophilia , World Federation , World Hemophilia Day , தெற்கு கொரியா , தெற்கு கொரியன் , வெளிப்படையான ஶ்ந்யாபெல் , உலகம் கூட்டமைப்பு ஆஃப் ஹீமோபிலியா , பச்சை குறுக்கு நிறுவனம் , உலகம் ஹீமோபிலியா , உலகம் கூட்டமைப்பு , உலகம் ஹீமோபிலியா நாள் ,

GC Pharma Submits Biologics License Application to US FDA for Immune Globulin 'GC5107'


Press release content from Business Wire. The AP news staff was not involved in its creation.
GC Pharma Submits Biologics License Application to US FDA for Immune Globulin ‘GC5107’
February 26, 2021 GMT
YONGIN, South Korea (BUSINESS WIRE) Feb 25, 2021
GC Pharma (006280.KS) today announced that it had submitted its Biologics License Application (BLA) for ‘GC5107’ (Immune Globulin Intravenous (Human),10% Liquid) to the United States Food and Drug Administration (FDA).
GC Pharma demonstrated positive results in a Phase III study in North America, meeting its primary efficacy endpoint of acute serious bacterial infections (SBI). In the trials included in the submission, with PI (Primary Humoral Immunodeficiency) patients, all primary efficacy and safety endpoints corresponding to FDA guidelines were satisfied. ....

United States , South Korea , Hyungoo Kang , Yelin Jun , Woosub Shin , Hansaem Kim , Eun Chul Huh , Drug Administration , Green Cross Corporation , Biologics License Application , Immune Globulin Intravenous , United States Food , North America , Primary Humoral Immunodeficiency , Cross Corporation , Business Wire , Pharmaceutical Manufacturing , Health Care Industry , Medical Biotechnology Industry , East Asia , ஒன்றுபட்டது மாநிலங்களில் , தெற்கு கொரியா , ஏன் சுல் ஹூ , பச்சை குறுக்கு நிறுவனம் , உயிரியல் உரிமம் விண்ணப்பம் , ஒன்றுபட்டது மாநிலங்களில் உணவு ,

Recombinant Vaccine Market by Type, Application and Forecast 2020 – 2027 | Key Players – Merck & Co., Inc., Green Cross Corporation, Pfizer, Inc. – KSU


decisivemarketsinsightsFebruary 16, 2021
 
Decisive Markets Insights Wants your organization to stay ahead of the competition and various other market dynamics. This can happen only when you go ahead and fill the pre-order inquiry form below –
In our sample, you will experience the entire overview of the Recombinant Vaccine market, its CAGR is expected to reach 5.8% during the forecast period 2020 – 2027, segmentation – By type, By application, and By geography.
Our plethora of details will give you a 360-degree perspective thereby encouraging you to partner with us for your research needs.
Take a step ahead to partner with one of the best research firms.
To inquire before purchasing the report, visit @ ....

United States , United Kingdom , South Korea , Asia Pacific , Sunil Kumar , Merck Co Inc , Glaxosmithkline Plc , Pfizer Inc , Porter Five , Protein Science Corporation , Extensive Research Methodology , Green Cross Corporation , Decisive Markets Insights Wants , Recombinant Vaccine , Recombinant Vaccine Market , Decisive Markets Insights , Sample Copy , North America , South America , Five Forces , Europe Covers Italy , Asia Pacific Covers India , Covers Middle East , Central America , Leverage Your Dollar , Help Impact Your Revenues ,

GC Pharma Reports Full Year 2020 Results


Press release content from Business Wire. The AP news staff was not involved in its creation.
GC Pharma Reports Full Year 2020 Results
February 9, 2021 GMT
YONGIN, South Korea (BUSINESS WIRE) Feb 9, 2021
GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited financial results for the year ended 31 December 2019.
Key Figures (1)
-
(1) Results from continuing operations (Green Cross MS’ blood bag business has been classified as discontinued operations)
(2) Results and percentages compare full financial year 2019
Financial Highlights
Delivered total revenue growth of 10.8% to KRW 1,504.1 billion (2019: 1,357.1 billion), and operation profit increased 20.6% to KRW 50.2 billion (2019: 41.7 billion) in the full year of 2020 ....

United States , South Korea , South Korean , Hyungoo Kang , Woosub Shin , Cross Labcell , Green Cross Corporation , Green Cross , Genef China , Cross Corporation , Business Wire , Corporate News , Pharmaceutical Manufacturing , Health Care Industry , East Asia , Earnings Reports , Medical Biotechnology Industry , Financial Performance , ஒன்றுபட்டது மாநிலங்களில் , தெற்கு கொரியா , தெற்கு கொரியன் , பச்சை குறுக்கு நிறுவனம் , பச்சை குறுக்கு , குறுக்கு நிறுவனம் , வணிக கம்பி , பெருநிறுவன செய்தி ,